Log in
NYSE:ABT

Abbott Laboratories Competitors

$105.93
-2.43 (-2.24 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$104.75
Now: $105.93
$109.00
50-Day Range
$100.92
MA: $106.43
$111.05
52-Week Range
$61.61
Now: $105.93
$114.19
Volume5.71 million shs
Average Volume7.14 million shs
Market Capitalization$187.55 billion
P/E Ratio61.23
Dividend Yield1.33%
Beta0.92

Competitors

Abbott Laboratories (NYSE:ABT) Vs. MDT, ISRG, SYK, BDX, BSX, and EW

Should you be buying ABT stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Abbott Laboratories, including Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), and Edwards Lifesciences (EW).

Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 24 consecutive years and Abbott Laboratories has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medtronic and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132212.85
Abbott Laboratories141202.65

Medtronic presently has a consensus target price of $117.8571, suggesting a potential upside of 7.90%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Abbott Laboratories' higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Risk & Volatility

Medtronic has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Abbott Laboratories9.89%17.34%7.94%

Valuation & Earnings

This table compares Medtronic and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.08$4.79 billion$4.5923.80
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69

Medtronic has higher earnings, but lower revenue than Abbott Laboratories. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Abbott Laboratories and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories9.89%17.34%7.94%
Intuitive Surgical24.45%12.35%10.63%

Volatility and Risk

Abbott Laboratories has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Insider & Institutional Ownership

73.1% of Abbott Laboratories shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69
Intuitive Surgical$4.48 billion19.04$1.38 billion$9.9573.21

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141202.65
Intuitive Surgical381202.39

Abbott Laboratories presently has a consensus price target of $114.3333, suggesting a potential upside of 7.93%. Intuitive Surgical has a consensus price target of $720.4737, suggesting a potential downside of 1.10%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Abbott Laboratories on 7 of the 13 factors compared between the two stocks.

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Stryker and Abbott Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.56$2.08 billion$8.2626.74
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69

Abbott Laboratories has higher revenue and earnings than Stryker. Stryker is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Abbott Laboratories9.89%17.34%7.94%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Stryker and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
Abbott Laboratories141202.65

Stryker presently has a consensus target price of $220.68, indicating a potential downside of 0.10%. Abbott Laboratories has a consensus target price of $114.3333, indicating a potential upside of 7.93%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Stryker.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 1 consecutive years.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Volatility & Risk

Becton, Dickinson and has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.30%14.19%5.86%
Abbott Laboratories9.89%17.34%7.94%

Analyst Recommendations

This is a summary of current ratings for Becton, Dickinson and and Abbott Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Abbott Laboratories141202.65

Becton, Dickinson and presently has a consensus target price of $280.8571, suggesting a potential upside of 18.81%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Becton, Dickinson and's higher possible upside, research analysts plainly believe Becton, Dickinson and is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Becton, Dickinson and and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.29 billion3.96$1.23 billion$11.6820.24
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

84.2% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dividends

Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.3%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has increased its dividend for 10 consecutive years and Abbott Laboratories has increased its dividend for 1 consecutive years.

Summary

Abbott Laboratories beats Becton, Dickinson and on 11 of the 18 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

73.1% of Abbott Laboratories shares are held by institutional investors. Comparatively, 90.2% of Boston Scientific shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Abbott Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141202.65
Boston Scientific031933.00

Abbott Laboratories currently has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Boston Scientific has a consensus target price of $45.00, suggesting a potential upside of 21.13%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories9.89%17.34%7.94%
Boston Scientific39.18%12.86%5.76%

Valuation and Earnings

This table compares Abbott Laboratories and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69
Boston Scientific$10.74 billion4.95$4.70 billion$1.5823.51

Boston Scientific has lower revenue, but higher earnings than Abbott Laboratories. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Abbott Laboratories on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Insider & Institutional Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Edwards Lifesciences has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences17.21%29.11%18.32%
Abbott Laboratories9.89%17.34%7.94%

Valuation and Earnings

This table compares Edwards Lifesciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion11.96$1.05 billion$1.8644.95
Abbott Laboratories$31.90 billion5.88$3.69 billion$3.2432.69

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Edwards Lifesciences and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251402.57
Abbott Laboratories141202.65

Edwards Lifesciences currently has a consensus target price of $86.0526, suggesting a potential upside of 2.92%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Edwards Lifesciences.


Abbott Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.4$109.23-0.1%$146.83 billion$28.91 billion33.40Analyst Revision
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$728.48-0.6%$85.25 billion$4.48 billion82.97Earnings Announcement
Insider Selling
Stryker logo
SYK
Stryker
1.9$220.90-0.0%$82.80 billion$14.88 billion52.47Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$236.40-0.1%$68.53 billion$17.29 billion85.04
Boston Scientific logo
BSX
Boston Scientific
2.1$37.15-1.0%$53.15 billion$10.74 billion13.17Upcoming Earnings
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$83.61-1.0%$51.98 billion$4.35 billion71.87Analyst Report
Unusual Options Activity
Heavy News Reporting
Baxter International logo
BAX
Baxter International
2.0$81.74-0.7%$41.38 billion$11.36 billion24.69Upcoming Earnings
Decrease in Short Interest
DexCom logo
DXCM
DexCom
1.5$387.84-1.2%$37.13 billion$1.48 billion177.10Upcoming Earnings
Analyst Upgrade
Insider Selling
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.2$419.73-0.1%$35.70 billion$2.41 billion79.34Upcoming Earnings
Analyst Upgrade
Heavy News Reporting
ResMed logo
RMD
ResMed
1.6$179.13-0.2%$25.96 billion$2.96 billion41.95Upcoming Earnings
Insider Selling
Hologic logo
HOLX
Hologic
1.9$65.85-0.8%$17.05 billion$3.37 billion26.66
Teleflex logo
TFX
Teleflex
1.5$359.06-0.8%$16.70 billion$2.60 billion35.34Upcoming Earnings
Insulet logo
PODD
Insulet
1.4$241.14-1.9%$15.83 billion$738.20 million861.25Decrease in Short Interest
Steris logo
STE
Steris
1.7$185.95-0.2%$15.82 billion$3.03 billion38.66Increase in Short Interest
Varian Medical Systems logo
VAR
Varian Medical Systems
1.2$171.86-0.0%$15.64 billion$3.23 billion55.98Upcoming Earnings
Masimo logo
MASI
Masimo
1.2$234.16-0.9%$12.87 billion$937.84 million60.66Upcoming Earnings
Analyst Upgrade
Insider Selling
ABIOMED logo
ABMD
ABIOMED
1.2$272.60-1.8%$12.28 billion$840.88 million78.56Upcoming Earnings
Increase in Short Interest
Hill-Rom logo
HRC
Hill-Rom
1.9$89.50-1.3%$5.96 billion$2.91 billion28.87
Globus Medical logo
GMED
Globus Medical
1.8$53.27-0.9%$5.21 billion$785.37 million61.94Upcoming Earnings
Analyst Report
Heavy News Reporting
Integra Lifesciences logo
IART
Integra Lifesciences
1.5$47.44-0.7%$4.00 billion$1.52 billion-1,581.33Upcoming Earnings
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$30.62-0.0%$3.97 billion$920.90 million-28.89
NuVasive logo
NUVA
NuVasive
1.6$51.44-1.9%$2.64 billion$1.17 billion-428.67Upcoming Earnings
Analyst Report
CONMED logo
CNMD
CONMED
1.4$83.82-1.0%$2.39 billion$955.10 million88.23Upcoming Earnings
Integer logo
ITGR
Integer
1.7$65.03-0.4%$2.14 billion$1.26 billion29.56Upcoming Earnings
AtriCure logo
ATRC
AtriCure
1.6$37.97-2.2%$1.71 billion$230.81 million-29.43Analyst Downgrade
Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$37.27-2.3%$1.50 billion$236.54 million-47.78Analyst Revision
Alphatec logo
ATEC
Alphatec
1.4$9.75-2.6%$757.56 million$113.43 million-8.71Analyst Report
CryoLife logo
CRY
CryoLife
2.2$18.58-0.5%$703.40 million$276.22 million-61.93
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$33.43-0.7%$646.04 million$459.95 million-28.33Upcoming Earnings
Analyst Report
Surmodics logo
SRDX
Surmodics
1.4$40.79-1.2%$554.99 million$100.08 million72.84Upcoming Earnings
Increase in Short Interest
AngioDynamics logo
ANGO
AngioDynamics
2.3$10.83-2.0%$411.03 million$264.16 million-2.44
Accuray logo
ARAY
Accuray
1.5$3.21-1.2%$292.75 million$382.93 million107.00Upcoming Earnings
Invacare logo
IVC
Invacare
1.4$7.43-1.1%$255.73 million$927.96 million-5.90Upcoming Earnings
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.01-4.0%$71.00 million$61.30 million-2.24
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.